Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial

BACKGROUND: Combining the antibiotic azithromycin and hydroxychloroquine induces airway immunomodulatory effects, with the latter also having in vitro antiviral properties. This may improve outcomes in patients hospitalised for coronavirus disease 2019 (COVID-19). METHODS: Placebo-controlled double-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivapalan, Pradeesh, Ulrik, Charlotte Suppli, Lapperre, Therese Sophie, Bojesen, Rasmus Dahlin, Eklöf, Josefin, Browatzki, Andrea, Wilcke, Jon Torgny, Gottlieb, Vibeke, Håkansson, Kjell Erik Julius, Tidemandsen, Casper, Tupper, Oliver, Meteran, Howraman, Bergsøe, Christina, Brøndum, Eva, Bødtger, Uffe, Bech Rasmussen, Daniel, Graff Jensen, Sidse, Pedersen, Lars, Jordan, Alexander, Priemé, Helene, Søborg, Christian, Steffensen, Ida E., Høgsberg, Dorthe, Klausen, Tobias Wirenfeldt, Frydland, Martin Steen, Lange, Peter, Sverrild, Asger, Ghanizada, Muhzda, Knop, Filip K., Biering-Sørensen, Tor, Lundgren, Jens D., Jensen, Jens-Ulrik Stæhr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186006/
https://www.ncbi.nlm.nih.gov/pubmed/34083403
http://dx.doi.org/10.1183/13993003.00752-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186006/
https://www.ncbi.nlm.nih.gov/pubmed/34083403
http://dx.doi.org/10.1183/13993003.00752-2021

Ejemplares similares